摘要
目的研究非小细胞肺癌(NSCLC)患者血浆P16基因突变对NSCLC发生、发展和预后估计的意义。方法应用聚合酶链反应(PCR)扩增P16基因第2外显子,并用单链构象多态性分析(SSCP)产物突变情况,再与各生物参数进行相关研究。结果10例健康人血浆中没有测到P16基因第2外显子突变;32例NSCLC患者血浆中有14例(43.75%)测到这种突变,其中,鳞癌、腺癌及腺鳞癌中突变率分别为57.1%(8/14),37.5%(6/16)和0(0/2),鳞癌中P16基因的突变率明显高于腺癌和腺鳞癌(P<0.05)。TNM分期Ⅰ,Ⅱ,Ⅲ,Ⅳ期NSCLC患者血浆P16基因突变率分别为25.0%(1/4),33.3%(3/9),50.0%(5/10)和55.5%(5/9),Ⅲ,Ⅳ期明显高于Ⅰ,Ⅱ期(P<0.05)。结论血浆循环核酸P16基因突变在NSCLC中有较高的检出率,并与肿瘤的临床分期和病理类型有关,血浆P16基因突变对NSCLC的诊断以及转移的预测具有重要价值。
Objective To study the clinical significance of P16 gene mutations in assessing development and prognosis of non-small cell lung cancer （NSCLC） in patients. Methods Exons 2 of P16 gene were amplified by polymerase chain reaction（PCR） . The mutations of products were analyzed by single-stranded conformation pulymorphism（SSCP）. The mutation status obtained by SSCP associated with related parameters was confirmed. Results PI6 gene exon 2 mutation was found in 12 of 32 NSCLC patients （37.5%, 12/32） while in 0 of 10 healthy .The mutation rate in squamous carcinoma, adenocareinoma and adenosquamous carcinoma was 57.1% （ 8/14 ） , 37.5 % （6/16 ） and 0 （ 0/2 ） , respectively. The rate in squamous carcinoma was higher than that in adenoearcinoma and adenosquamous carcinoma[ P 〈 0.05）. The PI6 gene exon 2 mutation rate in Ⅰ,Ⅱ,Ⅲ,Ⅳ stages was 25.0% （1/4） ,33,3% （3/9） ,50.0% （5/10）和 55.5% （5/9）, respectively.The rate of mutation in Ⅲ , Ⅳ stages NSCLC was higher than that in Ⅰ , Ⅱ stages（ P 〈 0.05）. Conclusion Plasma DNA P16 gene mutation has high detection rate in NSCLC and is associated with clinical staging and pathological type of tumor. It plays an important role in the diagnosis of NSCLC and metastasis prediction.
出处
《潍坊医学院学报》
2006年第6期433-434,共2页
Acta Academiae Medicinae Weifang
